Nanobiotix SA

Nanobiotix SA engages in research and development of nanoparticle-based technologies for the treatment of cancer. The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. It also engages in the development of magnetic particles and laser activated nanoparticles for the treatment and diagnosis of cancer. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

Nanobiotix S.A. (NASDAQ:NBTX ) Q4 2022 Results Conference Call April 25, 2023 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder and CEO Bart Van Rhijn - CFO Conference Call Participants Jonathan Miller - Evercore ISI Elliott Bosco - UBS Swayampakula Ramakanth - H.C.

Nanobiotix S.A. (NBTX) Q4 2022 Earnings Call Transcript

Pivotal Phase 3 trial NANORAY-312 ongoing globally with 104 sites activated in 25 countries to date; interim efficacy analysis after 67% of planned progression free survival (PFS) events expected in H2 2024, as planned Final data from Study 102 in head and neck cancer expected in H2 2023 First pancreatic cancer data expected from MD Anderson trial in H2 2023 Chief Medical Officer with strategically aligned multidisciplinary experience in oncology expected to join the company in Q3 2023 Reported €41.4 million in cash and cash equivalents as of December 31, 2022 2022 Universal Registration Document filed with the French financial market authority and the 2022 Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission Conference call and webcast scheduled for Tuesday, April 25 at 2:00 P.M. CEST/8:00 A.M.

NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results

Conference Call and Webcast to be Held at 2:00 PM CEST/8:00 AM EDT on April 25, 2023 PARIS and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announces it will issue its financial results for full-year ending December 31, 2022 and provide an operational update, on Monday, April 24, 2023, after the close of the US market.

NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023

PARIS and CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the company will postpone the release of its full year financial results initially scheduled for Tuesday, March 28, 2023 at 4:15 p.m. EDT and conference call initially scheduled for Wednesday, March 29, 2023.

Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call

Conference Call and Webcast to be Held at 2:00 P.M CET/8:00 A.M. EDT on March 29, 2023

Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

PARIS and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the first patient in the United States has been randomized in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma (“LA-HNSCC”) who are ineligible for platinum-based chemotherapy. NBTXR3 activated by radiotherapy will be evaluated alone or in combination with cetuximab. NBTXR3 is a potentially first-in-class radioenhancer with broad application across solid tumors, with prioritized focus in head and neck cancer.

NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

PARIS and CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it has ended the liquidity contract signed on October 23, 2012 with Gilbert Dupont. The termination is effective from December 20th, 2022, after the close of Euronext market.

NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement

PARIS and CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a virtual fireside chat at the 5th annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022, at 9:15 AM ET / 3:15 PM CET.

NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference

PARIS and CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced completion of the dose escalation part of a phase 1 dose escalation and dose expansion study evaluating potential first-in-class radioenhancer NBTXR3 for patients with locally advanced (LA) or borderline resectable (BR) pancreatic cancer (PC). The phase 1 study (“Study 2019-1001”) is being conducted by The University of Texas MD Anderson Cancer Center (MD Anderson).

NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer

Nanobiotix S.A. (NASDAQ:NBTX ) Q3 2022 Earnings Call Transcript November 10, 2022 8:00 AM ET Company Participants Kate Mcneil - Senior Vice President, Investor Relations Laurent Levy - Co-Founder & Chief Executive Officer Bart Van Rhijn - Chief Financial Officer Conference Call Participants Mike DiFiore - Evercore Clément Bassat - BNP Paribas Kate Mcneil Thank you, operator.

Nanobiotix S.A. (NBTX) Q3 2022 Earnings Call Transcript

Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST

NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer

PARIS and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and announced operational progress and cash position (unaudited) for the third quarter of 2022.

NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update

Multidisciplinary board includes twelve (12) experts from the United States and Europe that will support the development of lead therapeutic candidate NBTXR3 Multidisciplinary board includes twelve (12) experts from the United States and Europe that will support the development of lead therapeutic candidate NBTXR3

NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3

PARIS and Cambridge, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Jefferies London Healthcare Conference at 5:00 PM GMT/12:00 PM ET on Tuesday, November 15, 2022.

NANOBIOTIX to Present at the Jefferies London Healthcare Conference

Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10, 2022 Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10, 2022

NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022

PARIS and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced execution of a final agreement with the European Investment Bank (“EIB”) to re-align approximately €30.7 million in outstanding debt obligations with the Company's expected development and commercialization timelines. Nanobiotix previously announced agreement-in-principle with EIB for this restructuring on September 12th, 2022.

NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank

Nanobiotix S.A (NASDAQ:NBTX ) Q2 2022 Earnings Conference Call September 29, 2022 8:00 AM ET Company Participants Laurent Levy - Co-Founder, CEO Bart Van Rhijn - CFO Kate McNeil - IR Conference Call Participants Jon Miller - Evercore Suzanne van Voorthuizen - Kempen Kate McNeil Good afternoon and good morning. And welcome to Nanobiotix Conference Call to discuss our First Half 2022 Financial and Operational results.

Nanobiotix S.A (NBTX) Q2 2022 Earnings Call Transcript

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2022. “I am encouraged by the progress of NANORAY-312 as we, in partnership with LianBio, have been able to

Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2022, on Wednesday, September 28, 2022, after the close of the US market. The announcement will be followed by a conference call and live audio webc

Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced determination of the recommended phase 2 dose (RP2D) of NBTXR3 in combination with pembrolizumab or nivolumab for the treatment of patients suffering from inoperable locoregional recurrent (LRR) or recurrent and metastat

Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced reaching an agreement in principle to restructure €30.7 million in outstanding debt obligations related to the Company's 2018 loan agreement with the European Investment Bank (“EIB”). “The European Investment Bank has sh

Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024

LianBio

PARIS & CAMBRIDGE, Mass. & SHANGHAI, China & PRINCETON, N.J.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext: NANO – Nasdaq: NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, and LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets today announced randomization of the first patient in Asia in NANORAY-31

NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company'') (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, Co-Founder and Chief Executive Officer of Nanobiotix, has been named to the PharmaVoice 100 list of the most inspiring people in the life sciences. The prestigious annual li

NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company'') (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the H.C. Wainwright 24th Annual Global Investment Conference

Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today issued the Half-Year report on its liquidity contract with Gilbert Dupont. As of June 30, 2022, the following resources appeared on the liquidity account: - Number of shares: 25,706 - Cash balance: € 60,051.07 During the 1st Half

News for Nanobiotix SA Stock (NBTX)